Compound preparation for treating prostate carcinoma

摘要

Composition (A) comprising an inhibitor (I) of 5alpha -reductase; an estrogen receptor beta -agonist (II) and an inhibitor (III) of prostate-specific antigen (PSA), for simultaneous or sequential administration, is new. ACTIVITY : Cytostatic. Results for the effects of individual components on the growth of prostatic cancer cells are given but no results for the combination of (I)-(III). MECHANISM OF ACTION : Inhibition of 5alpha -reductase and PSA, and agonism of the estrogen receptor, resulting in reduced bioavailability of insulin-like growth factor -1 (which has a proliferation-stimulating effect) and reduced secretion of vascular endothelial growth factor (so inhibiting formation of new blood vessels).